AEterna Zentaris (NASDAQ: AEZS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AEterna Zentaris (NASDAQ: AEZS)

AEZS 2.720

-11.7%

Sep 3 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Gary Mohilner	2/25/2012 12:00:54 AM
	Read Replies (1) of 22

On Monday before the market opens KERX has a presentation where we should learn if the Phase III Trial has completed, is imminent, or is continuing. As I understand it we're already roughly 7 months past the last patient being dosed, if correct that's roughly 1.5 month beyond the anticipated median for the control group. If correct, it's also a half month before the median required for the Perifosine group would become fixed. That's not to say the median is 7.5 months, it could be 12 months or more, but if it were 7.5 months it couldn't go lower than that once all patients remaining alive in the trial have been in the trial beyond that point. I believe the benefit will be somewhere between 4 months and a full year, but as long as the control group hasn't dramatically improved over a lot of data that says even 5.5 months is high, even with worst case assumptions we ought to be beyond 2 months. The SPA in the Phase III Trial is for 2 months, so I believe we're there. Let's see if anyone's reading about AEZS here. Gary

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next